ANAESTHESIOLOGY - GENERAL ANAESTHESIA / LETTER TO EDITOR
Anabolic androgenic steroids and illicit drugs as potential modulating factors in malignant hyperthermia: a case series
1
Department of Anaesthesiology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil
2
Unimed – Aracatuba, Brazil
3
Unimed – Jundiai, Brazil
4
Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, Brazil
Submission date: 2025-05-19
Acceptance date: 2025-06-26
Publication date: 2025-07-23
Anaesthesiol Intensive Ther 2025;57(1):170-173
TOPICS
REFERENCES (30)
1.
Rüffert H, Bastian B, Bendixen D, Girard T, Heiderich S, Hellblom A, et al. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth 2021; 126: 120-130. DOI: 10.1016/j.bja.2020.09.029.
2.
Ibarra Moreno CA, Hu S, Kraeva N, Schuster F, Johannsen S, Rueffert H, et al. An assessment of penetrance and clinical expression of malignant hyperthermia in individuals carrying diagnostic ryanodine receptor 1 gene mutations. Anesthesiology 2019; 131: 983-991. DOI: 10.1097/ALN.0000000000002813.
3.
Monnier N, Krivosic-Horber R, Payen JF, Kozak-Ribbens G, Nivoche Y, Adnet P, et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002; 97: 1067-1074. DOI: 10.1097/00000542-200211000-00007.
4.
Riazi S, Kraeva N, Hopkins PM. Malignant hyperthermia in the post-genomics era: new perspectives on an old concept. Anesthesiology 2018; 128: 168-180. DOI: 10.1097/ALN.0000000000001878.
5.
Carpenter D, Robinson RL, Quinnell RJ, Ringrose C, Hogg M, Casson F, et al. Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth 2009; 103: 538-548. DOI: 10.1093/bja/aep204.
6.
Riazi S, Bersselaar LRVD, Islander G, Heytens L, Snoeck MMJ, Bjorksten A, et al. Pre-operative exercise and pyrexia as modifying factors in malignant hyperthermia (MH). Neuromuscul Disord 2022; 32: 628-634. DOI: 10.1016/j.nmd.2022.06.003.
7.
Butala B, Brandom B. Muscular body build and male sex are independently associated with malignant hyperthermia susceptibility. Can J Anaesth 2017; 64: 396-401. DOI: 10.1007/s12630-017-0815-2.
8.
Lassek WD, Gaulin SJC. Costs and benefits of fat-free muscle mass in men: relationship to mating success, dietary requirements, and native immunity. Evol Hum Behav 2009; 30: 322-328. DOI: https://doi.org/10.1016/j.evol....
9.
McCullough D, Webb R, Enright KJ, Lane KE, McVeigh J, Stewart CE, Davies IG. How the love of muscle can break a heart: impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health. Rev Endocr Metab Disord 2021; 22: 389-405. DOI: 10.1007/s11154-020-09616-y.
10.
Larach MG, Localio R, Allen GC, Denborough MA, Ellis FR, Gronert G, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-779. DOI: 10.1097/00000542-199404000-00008.
11.
Glahn KP, Ellis FR, Halsall PJ, Müller CR, Snoeck MM, Urwyler A, Wappler F; European Malignant Hyperthermia Group. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth 2010; 105: 417-420. DOI: 10.1093/bja/aeq243.
12.
Cong Z, Wan T, Wang J, Feng L, Cao C, Li Z, et al. Epidemiological and clinical features of malignant hyperthermia: a scoping review. Clin Genet 2024; 105: 233-242. DOI: 10.1111/cge.14475.
13.
Yuen B, Boncompagni S, Feng W, Yang T, Lopez JR, Matthaei KI, et al. Mice expressing T4826IRYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damage. FASEB J 2012; 26: 1311-1322. DOI: 10.1096/fj.11-197582.
14.
Lu Z, Rosenberg H, Li G. Prevalence of malignant hyperthermia diagnosis in hospital discharge records in California, Florida, New York, and Wisconsin. J Clin Anesth 2017; 39: 10-14. DOI: 10.1016/j.jclinane.2017.03.016.
15.
Migita T, Mukaida K, Kobayashi M, Hamada H, Kawamoto M. The severity of sevoflurane-induced malignant hyperthermia. Acta Anaesthesiol Scand 2012; 56: 351-356. DOI: 10.1111/j.1399-6576.2011.02573.x.
16.
Mello JM, Andrade PV, Santos JM, Oliveira ASB, Vainzof M, do Amaral JLG, Almeida da Silva HC. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study. Braz J Anesthesiol 2023; 73: 145-152. DOI: 10.1016/j.bjane.2022.06.010.
17.
Robinson RL, Carpenter D, Halsall PJ, Iles DE, Booms P, Steele D, et al. Epigenetic allele silencing and variable penetrance of malignant hyperthermia susceptibility. Br J Anaesth 2009; 103: 220-225. DOI: 10.1093/bja/aep108.
18.
Pelton LM, Maris SA, Loseke J. The effects of anabolic-androgenic steroids on gene expression in skeletal muscle: a systematic review. Int J Exerc Sci 2023; 16: 53-82. DOI: 10.70252/QFNY6413.
19.
Singh A, Kaur A, Stephens C, Fekete I, Nelson J, Kodwani N. Pulmonary haemorrhage and extensive arterial thrombosis with anabolic steroid abuse. BMJ Case Rep 2023; 16: e254817. DOI: 10.1136/bcr-2023-254817.
20.
Gnanapandithan K, Karthik N, Singh A. Rhabdomyolysis and acute kidney injury associated with anabolic steroid use. Am J Med 2019; 132: e652-e653. DOI: 10.1016/j.amjmed.2019.02.052.
21.
Malin A, Freyhoff J, Nobis W, Bone HG. Dialysis for severe rhabdomyolysis 7 days after multiple trauma. Anaesthesist 2012; 61: 224-228. DOI: 10.1007/s00101-012-1987-3.
22.
Farkash U, Shabshin N, Pritsch Perry M. Rhabdomyolysis of the deltoid muscle in a bodybuilder using anabolic-androgenic steroids: a case report. J Athl Train 2009; 44: 98-100. DOI: 10.4085/1062-6050-44.1.98.
23.
Hsieh CY, Chen CH. Rhabdomyolysis and pancreatitis associated with coadministration of danazol 600 mg/d and lovastatin 40 mg/d. Clin Ther 2008; 30: 1330-1335. DOI: 10.1016/s0149-2918(08)80058-6.
24.
Daniels JM, van Westerloo DJ, de Hon OM, Frissen PH. Rhabdomyolysis in a bodybuilder using steroids. Ned Tijdschr Geneeskd 2006; 150: 1077-1080 [Article in Dutch].
25.
Adamson R, Rambaran C, D’Cruz DP. Anabolic steroid-induced rhabdomyolysis. Hosp Med 2005; 66: 362. DOI: 10.12968/hmed.2005.66.6.18414.
26.
Braseth NR, Allison EJ Jr, Gough JE. Exertional rhabdomyolysis in a body builder abusing anabolic androgenic steroids. Eur J Emerg Med 2001; 8: 155-157. DOI: 10.1097/00063110-200106000-00015.
27.
Hageloch W, Appell HJ, Weicker H. Rhabdomyolysis in a bodybuilder using anabolic steroids. Sportverletz Sportschaden 1988; 2: 122-125. DOI: 10.1055/s-2007-993678 [Article in German].
28.
Capacchione JF, Radimer MC, Sagel JS, Kraus GP, Sambuughin N, Muldoon SM. Trauma, systemic inflammatory response syndrome, dietary supplements, illicit steroid use and a questionable malignant hyperthermia reaction. Anesth Analg 2009; 108: 900-903. DOI: 10.1213/ane.0b013e-31819240a5.
29.
Iftikhar MH, Dar AY, Haw A. Cocaine-induced rhabdomyolysis and compartment syndrome. BMJ Case Rep 2022; 15: e249413. DOI: 10.1136/bcr-2022-249413.
30.
Waldman W, Kabata PM, Dines AM, Wood DM, Yates C, Heyerdahl F, et al.; Euro-DEN Research Group. Rhabdomyolysis related to acute recreational drug toxicity – a Euro-DEN study. PLoS One 2021; 16: e0246297. DOI: 10.1371/journal.pone.0246297.
| eISSN: | 1731-2531 |
| ISSN: | 1642-5758 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
